Bio News
U.K.-based GSK said Japan’s Ministry of Health, Labour and Welfare approved Hepsavgo (bepirovirsen) as a functional cure for chronic hepatitis B. Hepsavgo is an antisense oligonucleotide that inhibits RNA production by the hepatitis B virus. The Japanese approval was based on results from the phase 3 B-Well trial, which confirmed a 19% functional cure rate among adults with low surface antigen levels.
Biobook Team
biobookmedia@biobook.co.krRural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
HLB Submits FDA Resubmission for First-Line Liver Cancer Treatment
Celltrion Reports Third-Quarter Revenue of 1.5 Trillion Won and Operating Profit of 510 Billion Won, Up 69% Year Over Year
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
